Last update Sept. 3, 2016
Very Low Risk
At latest update no published data on excretion into breast milk were found.
Pharmacokinetic data (moderately high molecular weight and high percentage of protein binding capacity) make unlikely the milk passage of significant amounts.
Intestinal absorption is also impaired by simultaneous food intake, minimizing any passage toward infant’s plasma.
Systemic use is authorized in neonates and infants
Competes with the ability of bilirubin in binding to albumin, so during the first month of life and especially in premature, the occurrence of neonatal jaundice must be monitored.
Take into account possible negative results of bacterial cultures in febrile infants when their mothers are using antibiotics.
DERMATOLOGICAL TOPICAL USE:
Poor absorption (0.54%) through the skin makes unlikely the passage of significant amount to breast milk.
Whenever necessary for treatment of infections in the nipple, apply right after breastfeed and let it to disaapear before the next feeding and if necessary remove excess with a gauze.
It should be avoided applying creams, gels and other products for local use on the nipple which could contain paraffin (mineral oil) in order to avoid any swallowing by the infant.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM